CYCC News Alert Cyclacel Pharmaceuticals (CYCC) 0.69 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cyclacel Pharmaceuticals (CYCC) 0.69 $CYCC

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

Cyclacel Pharmaceuticals Down 5.6%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Fri Dec 19, 10:10AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing penny stocks, down 5.6% to $0.68 on 1.2x average daily volume. Cyclacel Pharmaceuticals has traded 299,000 shares thus far today, vs. average volume of 243,000 shares per day. The stock has underperformed the Dow (-5.6% to the Dow's 0.2%) and underperformed the S&P 500 (-5.6% to the S&P's 0.3%) during today's trading.
CYCC: 0.69 (+0.01)

Cyclacel Now An Exercise In Futility
Stephen Simpson, CFA - at Seeking Alpha - Thu Dec 18, 5:30AM CST

CYCC: 0.69 (+0.01)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 88.18 (+0.89), CLDX: 17.08 (-0.18), CYCC: 0.69 (+0.01), IMMU: 4.41 (+0.13), EBS: 27.64 (+1.28), INCY: 71.57 (+1.99), TGTX: 16.03 (+0.33), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GILD: 91.29 (+1.84), CELGZ: 3.34 (-0.01)

Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), CYCC: 0.69 (+0.01), SCMP: 13.75 (+0.44)

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.69 (+0.01), CBST: 100.29 (-0.09), SPHS: 0.46 (+0.02), CCXI: 6.64 (-0.04), ALXN: 181.96 (+3.09), EXEL: 1.29 (-0.01)

Downgrade Alert for Cyclacel Pharmaceuticals (CYCC)
Comtex SmarTrend(R) - Wed Dec 17, 6:51AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $0.68 on volume of 5.4 million shares, above average daily volume of 68,000. Over the past year, Cyclacel Pharmaceuticals has traded in a range of $0.66 to $4.84 and closed yesterday at $0.68, 3% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.6% while the 200-day MA has slid 0.8%.
CYCC: 0.69 (+0.01)

Nasdaq stocks posting largest volume increases
AP - Tue Dec 16, 5:41PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
QCCO: 1.75 (+0.03), CYCC: 0.69 (+0.01), RVBD: 20.35 (+0.01), NECB: 6.98 (-0.13), ISIG: 3.78 (+0.02), HGSH: 4.60 (-0.06), LNBB: 17.75 (-0.23), AIRT: 24.17 (+0.03), KFFB: 8.25 (+0.10), SMBC: 37.01 (+0.01), IROQ: 16.83 (-0.12), MFI: 10.19 (unch)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:47AM CST

FRO: 2.43 (-0.01), TLM: 7.84 (unch), ECR: 6.98 (+0.09), BBX: 16.67 (-0.07), WG: 6.07 (-0.13), HGSH: 4.60 (-0.06), NVGN: 2.40 (-0.09), TPLM: 5.74 (-0.41), TLOG: 4.45 (-0.09), CYCC: 0.69 (+0.01), SFY: 4.47 (-0.06), BBG: 11.46 (-0.24), WRES: 1.66 (-0.13), GOL: 5.16 (-0.04), NAV: 33.81 (-0.11), WYY: 1.33 (-0.03), FNJN: 2.46 (+0.18), LINE: 10.93 (-0.32), SCX: 19.06 (+0.12), WLDN: 12.77 (+0.45)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:10AM CST

FRO: 2.43 (-0.01), TLM: 7.84 (unch), PHMD: 1.46 (-0.03), SLXP: 114.92 (-1.18), BBEP: 7.06 (-0.23), EXAS: 27.60 (+0.39), NVGN: 2.40 (-0.09), MBT: 8.11 (+0.06), LPI: 10.61 (-0.35), CYCC: 0.69 (+0.01), GOL: 5.16 (-0.04), AUY: 3.89 (+0.15), ORAN: 17.52 (-0.04), YNDX: 17.66 (-0.32)

Cyclacel's sapacitabine unlikely to achieve efficacy endpoint in Phase 3 AML trial
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:11AM CST

CYCC: 0.69 (+0.01)

Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
GlobeNewswire - Tue Dec 16, 6:00AM CST
- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study -
CYCC: 0.69 (+0.01), CYCCP: 6.18 (+0.18)

Cyclacel ups revenues 133% in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:32AM CST

CYCC: 0.69 (+0.01)

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:24PM CST

CYCC: 0.69 (+0.01)

Cyclacel Pharmaceuticals misses by $0.06
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:09PM CST

CYCC: 0.69 (+0.01)

Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2014.
CYCC: 0.69 (+0.01), CYCCP: 6.18 (+0.18)

Cyclacel reports November 11
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 11:09AM CST

CYCC: 0.69 (+0.01)

Cyclacel Pharmaceuticals to Release 2014 Third Quarter Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 11, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
CYCC: 0.69 (+0.01), CYCCP: 6.18 (+0.18)

Cyclacel Provides SEAMLESS Study Update on Sapacitabine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 5:25PM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) provided an update on its cancer candidate, sapacitabine.
MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), AUXL: 34.40 (+0.18), LGND: 51.79 (+1.22)

Exact Sciences (EXAS) Looks Strong: Stock Surges 35.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:44AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares surge a massive 36% on the day
EBS: 27.64 (+1.28), CYCC: 0.69 (+0.01), FCSC: 2.38 (+0.04), EXAS: 27.60 (+0.39)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 139

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 94

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 108

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 65

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading